Price Alert

Pacira BioSciences Inc. (PCRX)

NASDAQ: PCRX · Real-Time Price · USD

26.73

-0.45 (-1.66%)

At close: Sep 04, 2025, 3:59 PM

26.73

0.00%

After-hours: Sep 04, 2025, 04:10 PM EDT

-1.66% (1D)

Bid	25.25
Market Cap	1.2B
Revenue (ttm)	705.85M
Net Income (ttm)	-127.46M
EPS (ttm)	-2.75
PE Ratio (ttm)	-9.72
Forward PE	8.35
Analyst	Buy

Ask	28.6
Volume	767,379
Avg. Volume (20D)	650,903
Open	27.19
Previous Close	27.18
Day's Range	26.52 - 27.64
52-Week Range	12.61 - 27.64
Beta	0.48

About PCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Pacira BioSciences Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+14.67%

Pacira BioSciences shares are trading higher after... Unlock content with Pro Subscription

5 months ago

-0.82%

Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.

News

4 weeks ago · seekingalpha.com

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Brendan P. Teehan - Chief Commercial Officer Frank D.

1 month ago · zacks.com

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

2 months ago · zacks.com

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

2 months ago · accessnewswire.com

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...